134 related articles for article (PubMed ID: 24007982)
1. Use of denosumab for renal cell carcinoma-associated malignant hypercalcemia: a case report and review of the literature.
Freeman A; El-Amm J; Aragon-Ching JB
Clin Genitourin Cancer; 2013 Dec; 11(4):e24-6. PubMed ID: 24007982
[No Abstract] [Full Text] [Related]
2. Denosumab should be the treatment of choice for bisphosphonate refractory hypercalcaemia of malignancy.
Adhikaree J; Newby Y; Sundar S
BMJ Case Rep; 2014 Jan; 2014():. PubMed ID: 24481018
[TBL] [Abstract][Full Text] [Related]
3. Denosumab for the treatment of bisphosphonate-refractory hypercalcemia.
Boikos SA; Hammers HJ
J Clin Oncol; 2012 Oct; 30(29):e299. PubMed ID: 22949145
[No Abstract] [Full Text] [Related]
4. Denosumab for the management of hypercalcemia of malignancy in patients with multiple myeloma and renal dysfunction.
Cicci JD; Buie L; Bates J; van Deventer H
Clin Lymphoma Myeloma Leuk; 2014 Dec; 14(6):e207-11. PubMed ID: 25128013
[No Abstract] [Full Text] [Related]
5. Denosumab for post-transplantation hypercalcemia in osteopetrosis.
Shroff R; Beringer O; Rao K; Hofbauer LC; Schulz A
N Engl J Med; 2012 Nov; 367(18):1766-7. PubMed ID: 23113501
[No Abstract] [Full Text] [Related]
6. Resistant hypercalcaemia in metastatic parathyroid carcinoma.
Bowyer SE; White AM; Ransom DT; Davidson JA
Med J Aust; 2013 Jun; 198(10):559-61. PubMed ID: 23725272
[No Abstract] [Full Text] [Related]
7. Denosumab for tumor-induced hypercalcemia complicated by renal failure.
Bech A; de Boer H
Ann Intern Med; 2012 Jun; 156(12):906-7. PubMed ID: 22711097
[No Abstract] [Full Text] [Related]
8. Letter to the editor: denosumab for “resistant” hypercalcemia in patients with impaired renal function.
Arampatzis S
J Clin Endocrinol Metab; 2015 Jan; 100(1):L6. PubMed ID: 25559545
[No Abstract] [Full Text] [Related]
9. Denosumab may reduce hypercalcaemia after transplantation for osteopetrosis.
BMJ; 2012 Nov; 345():e7477. PubMed ID: 23135199
[No Abstract] [Full Text] [Related]
10. Using denosumab to treat immobilization hypercalcemia in a post-acute care patient.
Booth KA; Hays CI
J Clin Endocrinol Metab; 2014 Oct; 99(10):3531-5. PubMed ID: 25033064
[TBL] [Abstract][Full Text] [Related]
11. Denosumab for treatment of hypercalcemia of malignancy.
Hu MI; Glezerman IG; Leboulleux S; Insogna K; Gucalp R; Misiorowski W; Yu B; Zorsky P; Tosi D; Bessudo A; Jaccard A; Tonini G; Ying W; Braun A; Jain RK
J Clin Endocrinol Metab; 2014 Sep; 99(9):3144-52. PubMed ID: 24915117
[TBL] [Abstract][Full Text] [Related]
12. [RANKL inhibition in bone metastases].
Wada T
Nihon Yakurigaku Zasshi; 2013 Jan; 141(1):22-6. PubMed ID: 23302944
[No Abstract] [Full Text] [Related]
13. Use of denosumab in parathyroid carcinoma with refractory hypercalcemia.
Tong CV; Hussein Z; Noor NM; Mohamad M; Ng WF
QJM; 2015 Jan; 108(1):49-50. PubMed ID: 25099611
[No Abstract] [Full Text] [Related]
14. Resorptive hypercalcemia in post-essential thrombocythemia myelofibrosis: treatment with denosumab.
Khoury N; Chang J; Gru AA; Whyte MP
J Clin Endocrinol Metab; 2012 Sep; 97(9):3051-5. PubMed ID: 22730513
[TBL] [Abstract][Full Text] [Related]
15. Critical hypercalcemia following discontinuation of denosumab therapy for metastatic giant cell tumor of bone.
Gossai N; Hilgers MV; Polgreen LE; Greengard EG
Pediatr Blood Cancer; 2015 Jun; 62(6):1078-80. PubMed ID: 25556556
[TBL] [Abstract][Full Text] [Related]
16. Bisphosphonate or RANK-L inhibitor for tumour-induced hypercalcaemia?
Bech A; Essink G; de Boer H
Neth J Med; 2012 Jun; 70(5):250-1. PubMed ID: 22744931
[No Abstract] [Full Text] [Related]
17. Denosumab for patients with persistent or relapsed hypercalcemia of malignancy despite recent bisphosphonate treatment.
Hu MI; Glezerman I; Leboulleux S; Insogna K; Gucalp R; Misiorowski W; Yu B; Ying W; Jain RK
J Natl Cancer Inst; 2013 Sep; 105(18):1417-20. PubMed ID: 23990665
[TBL] [Abstract][Full Text] [Related]
18. Denosumab for management of parathyroid carcinoma-mediated hypercalcemia.
Vellanki P; Lange K; Elaraj D; Kopp PA; El Muayed M
J Clin Endocrinol Metab; 2014 Feb; 99(2):387-90. PubMed ID: 24178790
[TBL] [Abstract][Full Text] [Related]
19. Effect of antiresorptive drugs on bony turnover in the jaw: denosumab compared with bisphosphonates.
Ristow O; Gerngroß C; Schwaiger M; Hohlweg-Majert B; Kehl V; Jansen H; Hahnefeld L; Koerdt S; Otto S; Pautke C
Br J Oral Maxillofac Surg; 2014 Apr; 52(4):308-13. PubMed ID: 24582013
[TBL] [Abstract][Full Text] [Related]
20. Refractory hypercalcaemia secondary to parathyroid carcinoma: response to high-dose denosumab.
Karuppiah D; Thanabalasingham G; Shine B; Wang LM; Sadler GP; Karavitaki N; Grossman AB
Eur J Endocrinol; 2014 Jul; 171(1):K1-5. PubMed ID: 24743399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]